AI assistant
Coloplast — Investor Presentation 2016
Jun 22, 2016
3358_rns_2016-06-22_c436610a-ce19-4012-8a6d-17c5f2bbc253.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Coloplast
Ostomy Care
Urology & Continence Care
Wound & Skin Care
Announcement No. 7/2016
22 June 2016
Coloplast A/S
Holtedam 1
3050 Humlebæk
Denmark
Tel: +45 4911 1111
www.coloplast.com
CVR-nr. 69749917
Capital Markets Day 2016 provides new long-term guidance
Coloplast is hosting a Capital Markets Day today at 08:15-16:30 (CDT) in Minneapolis, USA.
The Board of Directors has approved a new long-term financial guidance, spanning 3 years, consisting of:
- Organic revenue growth of 7-9% p.a.
- EBIT-margin expansion of ½-1%-points p.a.
The previous long-term guidance was issued in connection with our Capital Markets Day in 2014 and consisted of an organic revenue growth of 7-10% p.a. and an EBIT margin expansion of ½-1%-points p.a.
The change in the long-term organic revenue growth guidance from 7-10% p.a. to 7-9% p.a. is explained by the challenging macroeconomic environment in Emerging markets.
The financial guidance for 2015/16 is unchanged at an organic revenue growth of 7-8% at constant exchange rates and an EBIT margin of 33-34% at constant exchange rates.
At our Capital Markets Day we will provide a strategic update on Coloplast and a financial perspective on Coloplast's strategy including the new long-term guidance. We will also provide an update on our business areas as well as a deep dive into the US market.
The day will include the following presentations:
- Group Strategy Update by Lars Rasmussen, CEO
- Financial Outlook by Anders Lonning-Skovgaard, CFO
- Urology Care Update by Steffen Eichner Hovard, SVP Urology Care
- Wound Care Update by Nicolai Buhl Andersen, SVP Wound Care
- Chronic Care Update by Kristian Villumsen, EVP Chronic Care
- US Healthcare System and Reimbursement by Mark Draper, Head of Public Affairs
- US Acute Market Structure by Richard McEnroe, Director Chronic Care National Sales, US
- US Community Market Structure by Morten Hansen, VP Sales and Marketing, US
- Coloplast North America by Edmond Veome, SVP Chronic Care Management, NA
The presentations from the event will be available on June 22 at around 09:00 (CDT) at the following link:
http://www.coloplast.com/investor-relations/events/#section=333511
A webcast of the presentations from the event will also be available on our website within one week.
Anders Lonning-Skovgaard
CFO
1/2
Coloplast
Ostomy Care
Urology & Continence Care
Wound & Skin Care
For further information, please contact
Investors and analysts
Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 1301
Email: [email protected]
Ellen Bjurgert
Investor Relations Manager
Tel. +45 4911 1800 / +45 4911 3376
E-mail: [email protected]
Press and the media
Maria Lindeberg
Sr. Media Relations Manager, Corporate Communications
Tel. +45 4911 3095
E-mail: [email protected]
This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 10,000 people.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2016-06 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.